Economic burden of renal cell carcinoma: Part I an updated review

PharmacoEconomics

Volumn 29, Issue 4, 2011, Pages 315-329

  Shih, Ya Chen T ^a   Chien, Chun Ru ^b   Xu, Ying ^a   Pan, I Wen ^a   Smith, Grace L ^a   Buchholz, Thomas A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Antineoplastics; Bevacizumab; Cost analysis; Cost effectiveness; Renal cell carcinoma; Sorafenib, therapeutic use; Sunitinib, therapeutic use; Temsirolimus; therapeutic use; treatment

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; BEVACIZUMAB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VINBLASTINE;

COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; CRYOABLATION; DRUG MEGADOSE; HUMAN; KIDNEY CARCINOMA; LAPAROSCOPIC SURGERY; LOW DRUG DOSE; PARTIAL NEPHRECTOMY; PRIORITY JOURNAL; REVIEW;

CARCINOMA, RENAL CELL; COST OF ILLNESS; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; HUMANS;

EID: 79952687479     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11586100-000000000-00000     Document Type: Review

References (57)

1. Wallen EM, Pruthi RS, Joyce GF, et al. Kidney cancer. J Urol 2007; 177 (6): 2006-18
2. Winer E, Gralow J, Diller L, et al. Clinical cancer advances 2008: major research advances in cancer treatment, preven-tion, and screening: a report from the American Society of Clinical Oncology. J Clin Oncol 2009 Feb 10; 27 (5): 812-26
3. Jewett MA, Zuniga A. Renal tumor natural history: the rationale and role for active surveillance. Urol Clin North Am 2008 Nov; 35 (4): 627-34
4. National Cancer Institute. Surveillance Epidemiology and End Results (SEER) [online]. Available from URL: http://seer.cancer.gov/statfacts/html/ kidrp.html [Accessed 2009 Sep 30]
5. National Comprehensive Cancer Network. Clinical practice guideline in oncology. Kidney cancer v.1.2010 [online]. Available from URL: http://www.nccn.org/professionals/physician-gls/PDF/kidney.pdf[Accessed 2009 Sep 18]
6. Lang K, Danchenko N, Gondek K, et al. The burden of illness associated with renal cell carcinoma in the United States. Urol Oncol 2007 Sep-Oct; 25 (5): 368-75 (Pubitemid 47362759)
7. Hu J, Chen Y, Mao Y, et al. Alcohol drinking and renal cell carcinoma in Canadian men and women. Cancer Detect Prev 2008; 32 (1): 7-14
8. Hu J, La Vecchia C, Negri E, et al. Dietary vitamin C, E, and carotenoid intake and risk of renal cell carcinoma. Cancer Causes Control 2009 Jun 17; 20 (8): 1451-8
9. Zhang Y, Cantor KP, Lynch CF, et al. A population-based case-control study of occupation and renal cell carcinoma risk in Iowa. J Occup Environ Med 2004 Mar; 46 (3): 235-40 (Pubitemid 38366627)
10. Gudbjartsson T, Hardarson S, Petursdottir V, et al. Histological subtyping and nuclear grading of renal cell carci-noma and their implications for survival: a retrospective nation-wide study of 629 patients. Eur Urol 2005 Oct; 48 (4): 593-600 (Pubitemid 41278584)
11. Scoll B J, Wong YN, Egleston BL, et al. Age, tumor size and relative survival of patients with localized renal cell carci-noma: a surveillance, epidemiology and end results anal-ysis. J Urol 2009 Feb; 181 (2): 506-11
12. Halbert RJ, Figlin RA, Atkins MB, et al. Treatment ofpatients with metastatic renal cell cancer: a RAND Appropriateness Panel. Cancer 2006 Nov 15; 107 (10): 2375-83 (Pubitemid 44748520)
13. Mickisch G, Carballido J, Hellsten S, et al. Guidelines on renal cell cancer. Eur Urol 2001 Sep; 40 (3): 252-5 (Pubitemid 34701894)
14. Hailey D. Radiofrequency ablation in the treatment ofkidney cancer. Issues Emerg Health Technol 2006 Feb; (80): 1-4
15. McDermott DF, Atkins MB. Application ofIL-2 and other cytokines in renal cancer. Expert Opin Biol Ther 2004 Apr; 4 (4): 455-68 (Pubitemid 38480546)
16. American Cancer Society. Detailed guide: kidney cancer, biologic therapy (immunotherapy) [online]. Available from URL: http://www.cancer.org/cancer/ kidneycancer/detai ledguide/kidney-cancer-adult-treating-immunotherapy [Accessed 2011 Jan 20]
17. Mulder SF, van Spronsen DJ, De Mulder PH. Do the results of the new trials change the standard treatment of meta-static renal cell cancer? Onkologie 2007 May; 30 (5): 260-4 (Pubitemid 46674909)
18. Thomas AA, Rini BI, Lane BR, et al. Response of the primary tumor to neoadjuvant sunitinib in patients with ad-vancedrenalcellcarcinoma. JUrol2009 Feb; 181 (2): 518-23
19. Speca J, Yenser S, Creel P, et al. Improving outcomes with novel therapies for patients with newly diagnosed renal cell carcinoma. Clin Genitourin Cancer 2006 Dec; 5 Suppl. 1: S24-30
20. No authors listed. Temsirolimus (Torisel) for advanced renal cell carcinoma. Med Lett Drugs Ther 2007 Dec 17; 49 (1276): 103-4
21. No authors listed. Two new drugs for renal cell carcinoma. Med Lett Drugs Ther 2007 Feb 26; 49 (1255): 18-20
22. Motzer RJ, Basch E. Targeted drugs for metastatic renal cell carcinoma. Lancet 2007 Dec 22; 370 (9605): 2071-3 (Pubitemid 350296281)
23. Cella D. Quality oflife in patients with metastatic renal cell carcinoma: the importance ofpatient-reported outcomes. Cancer Treat Rev 2009 Dec; 35 (8): 733-7
24. No authors listed. Welcome clinical leadership at NICE. Lancet 2008 Aug 23; 372 (9639): 601
25. Drummond M, Evans B, LeLorier J, et al. Evidence and values: requirements for public reimbursement ofdrugs for rare diseases: a case study in oncology. Can J Clin Phar-macol 2009; 16 (2): e273-81; discussion e82-4
26. Eisen T. The National Institute of Health and Clinical Excellence rejects new treatments for renal cell cancer: Cin-derella'sinvitation iscancelled. BJUInt2008Dec; 102(11): 1491-2
27. Mayor S. NICE recommends kidney cancer drug it previously rejected on cost grounds. BMJ 2009; 338: b499
28. O'Dowd A. Watchdog set to reject four drugs for kidney cancer on the NHS. BMJ 2008; 337: a1262
29. Shih Y-CT, Chien C-R, Xu Y, et al. Economic burden ofrenal cell carcinoma. Part II-an updated analysis. Pharmaco-economics 2011; 29 (4): 331-41
30. Joudi FN, Allareddy V, Kane CJ, et al. Analysis of complications following partial and total nephrectomy for renal cancer in a population based sample. J Urol 2007 May; 177 (5): 1709-14 (Pubitemid 46560669)
31. Link RE, Permpongkosol S, Gupta A, et al. Cost analysis of open, laparoscopic, and percutaneous treatment options for nephron-sparing surgery. J Endourology 2006; 20 (10): 782-9 (Pubitemid 44736257)
32. Park S, Pearle MS, Cadeddu JA, et al. Laparoscopic and open partial nephrectomy: cost comparison with analysis of in-dividual parameters. J Endourol 2007 Dec; 21 (12): 1449-54
33. Tsavaris N, Skarlos D, Bacoyiannis C, et al. Combined treatment with low-dose interferon plus vinblastine is associated with less toxicity than conventional interferon monotherapy in patients with metastatic renal cell carci-noma. J Interferon Cytokine Res 2000 Aug; 20 (8): 685-90 (Pubitemid 30639091)
34. Duh MS, Dial E, Choueiri TK, et al. Cost implications of IV versus oral anti-angiogenesis therapies in patients with advanced renal cell carcinoma: retrospective claims data-base analysis. Curr Med Res Opin 2009 Aug; 25 (8): 2081-90
35. Mickisch G, Gore M, Escudier B, et al. Costs ofmanaging adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with inter-feron-alpha2a compared with sunitinib. Br J Cancer 2010 Jan 5; 102 (1): 80-6
36. Pandharipande PV, Gervais DA, Mueller PR, et al. Radiofrequency ablation versus nephron-sparing surgery for small unilateral renal cell carcinoma: cost-effectiveness analysis. Radiology 2008 Jul; 248 (1): 169-78
37. Remak E, Charbonneau C, Negrier S, et al. Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma. J Clin Oncol 2008 Aug 20; 26 (24): 3995-4000
38. Thompson Coon J, Hoyle M, Green C, et al. Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation. Health Technol Assess 2010; 14(2): 1-184
39. Hoyle M, Green C, Thompson-Coon J, et al. Cost-effectiveness of temsirolimus for first line treatment ofadvanced renal cell carcinoma. Value Health 2009 Sep 25; 13 (1): 61-8
40. Hoyle M, Green C, Thompson-Coon J, et al. Cost-effectiveness ofsorafenib for second-line treatment ofadvanced renal cell carcinoma. Value Health 2009 Sep 25; 13 (1): 55-60
41. Purmonen T, Martikainen JA, Soini EJ, et al. Economic evaluation of sunitinib malate in second-line treatment of metastatic renal cell carcinoma in Finland. Clin Ther 2008 Feb; 30 (2): 382-92 (Pubitemid 351474383)
42. Evans CP. Follow-up surveillance strategies for genitourinary malignancies. Cancer 2002 Jun 1; 94 (11): 2892-905 (Pubitemid 34547688)
43. Burnet NG, Jefferies SJ, Benson RJ, et al. Years oflife lost (YLL) from cancer is an important measure of population burden and should be considered when allocating research funds. Br J Cancer 2005; 92 (2): 241-5 (Pubitemid 40343136)
44. Yabroff KR, Davis WW, Lamont EB, et al. Patient time costs associated with cancer care. J Natl Cancer Inst 2007 Jan 3; 99 (1): 14-23
45. Yabroff KR, Kim Y. Time costs associated with informal caregiving for cancer survivors. Cancer 2009 Sep 15; 115 (18 Suppl.): 4362-73
46. Yabroff KR, Lamont EB, Mariotto A, et al. Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst 2008 May 7; 100 (9): 630-41
47. Mantovani LG, Morsanutto A, Tosolini F, et al. The burden of renal cell cancer: a retrospective longitudinal study on occurrence, outcomes and cost using an administrative claims database. Eur J Cancer Suppl 2008 October; 6 (14): 46-51
48. Shih YC, Halpern MT. Economic evaluations ofmedical care interventions for cancer patients: how, why, and what does it mean? CA Cancer J Clin 2008 Jul-Aug; 58 (4): 231-44
49. US Department of Labor. Bureau of Labor Statistics. Consumer price index, US medical care services [online]. Available from URL: http://www.bls.gov/data/ [Accessed 2009 Nov 23]
50. International Monetary Fund. World economic and financial surveys [online]. Available from URL: http://www. imf.org/external/pubs/ft/weo/2009/02/ weodata/index.aspx [Accessed 2009 Nov 23]
51. Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 1999 Nov 27; 354 (9193): 1896-900
52. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment ofmetastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007 Dec 22; 370 (9605): 2103-11 (Pubitemid 350296300)
53. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007 Jan 11; 356 (2): 115-24 (Pubitemid 46089672)
54. Litwin MS, Saigal CS, Yano EM, et al. Urologic Diseases in America Project: analytical methods and principal find-ings. J Urol 2005 Mar; 173 (3): 933-7 (Pubitemid 40239368)
55. Brown ML, Riley GF, Schussler N, et al. Estimating health care costs related to cancer treatment from SEER-Medi-care data. Med Care 2002 Aug; 40 (8 Suppl.): IV-104-17
56. Bridges JF, Onukwugha E, Mullins CD. Healthcare rationing by proxy: cost-effectiveness analysis and the misuse of the $50 000 threshold in the US. Pharmacoeconomics 2010; 28 (3): 175-84
57. Gupta K, Miller JD, Li JZ, et al. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev 2008 May; 34 (3): 193-205